Pharmalucence gets FDA approval for generic Cardiolite

07/20/2009 | Mass High Tech (Boston)

The FDA gave radiopharmaceutical supplier Pharmalucence the green light to develop and market a generic version of Lantheus Medical Imaging's Cardiolite, a diagnostic imaging agent for coronary artery disease. Pharmalucence's product, the Kit for the Preparation of Technetium Tc-99m Sestamibi Injection, is used for identifying myocardial ischemia and infarction.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA